Study objectives: To determine whether 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) singlephoton emission CT (SPECT) is useful in characterizing pulmonary masses. Design: Scans were prospectively acquired and interpreted. Interpretations were performed with CT or chest radiograph but interpreters were blinded to eventual diagnosis. Setting: University hospital practice and affiliated Veterans Administration medical center. Patients or participants: Forty patients participated as part of an institutional review boardapproved research protocol, and informed consent was obtained in all. Eight additional patient scans were acquired as part of their clinical evaluation for pulmonary mass. Measurements and results: There were 26 malignant lesions (12 were 1 to 2 cm in size, the rest were larger) and 17 benign lesions (3 were < 1 cm in size, 9 were 1 to 2 cm in size, and 5 were larger). Averaged sensitivity, specificity, positive predictive value, and negative predictive value were, respectively, 50% (12 of 24), 94% (17 of 18), 92% (12 of 13), and 59% (17 of 29) for lesions 1 to 2 cm in size, 100% (28 of 28), 90% (9 of 10), 97% (28 of 29), and 100% (9 of 9) for lesions > 2 cm in size. There was good correlation between readers (p < 0.0001). Conclusion: FDG SPECT is useful in characterizing pulmonary masses > 2 cm in size and appears to be equivalent to positron emission tomography for these lesions. Although currently clinically suboptimal for characterizing lesions < 2 cm in size, FDG SPECT appears to be better than current anatomic imaging methods. In addition, the positive predictive value of FDG SPECT for small lesions is also high (92%), and this technique appears potentially useful in the subset of patients in whom a positive result would alter clinical diagnostic pathways or care.
C
ancer statisticians estimate 171,500 new lung cancers would be detected in 1998. 1 Because only one third of malignancies present as nodules, and 35% of nodules found on chest radiographs (CXRs) are malignant, it could be estimated 2 that approximately 152,000 new pulmonary nodules would be found in 1998. Conventional imaging techniques are able to differentiate benign from malignant pulmonary nodules in only a small percentage of cases before biopsy or other interventional procedures. 3, 4 An accurate, cost-effective, accessible method to noninvasively determine whether a pulmonary nodule is benign or malignant could decrease patient morbidity and health-care resources and dollars now devoted to evaluation of pulmonary lesions.
The literature has shown that 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) uptake in a solitary pulmonary nodule determined by positron emission tomography (PET) imaging demonstrates malignancy with a high degree of accuracy, [5] [6] [7] [8] [9] but PET scanners are not accessible to a large number of patients. Single-photon emission CT (SPECT) imaging of FDG is feasible, 10 is relatively inexpensive, and has been validated by several authors for imaging viable myocardium. 11, 12 Although the resolution of FDG SPECT does not approach that of PET equipment at this time and use of FDG SPECT for tumor imaging is controversial, 13, 14 SPECT equip-ment adapted for high-energy imaging offers many practical solutions to some of the prohibitive aspects of clinical PET.
We undertook a prospective investigation of FDG SPECT in patients with lung masses to determine preliminary sensitivity and specificity of the technique.
Materials and Methods
Forty-eight patients with pulmonary masses were evaluated prospectively from February 1994 to December 1997. Patients with indeterminate masses-on CXR or CT-were recruited. Initially patients with large masses were included in the study; once adequate imaging results were established, emphasis switched to lesions Յ 4 cm in size. Forty studies were performed as a research investigation approved by the institutional review board of our health science center, and informed consent was obtained from all 40 patients. In these patients, clinicians were blinded to the results of the FDG study, and imaging results had no impact on clinical care. Eight studies were performed as clinical cases, and imaging results were used in combination with results of other tests in determining appropriate care.
Patients reported with a minimum of 4-h fast except in three patients: two with diabetes who ate a light lunch or snack approximately 1 to 2 h before injection and one patient who did not disclose mild hearing impairment at the time of recruitment and did not comply with instructions given over the telephone. After informed consent, doses of 185 to 444 MBq (5 to 12 mCi) were given IV and SPECT imaging was performed after a 45-to 120-min delay. FDG was prepared at a remote site the morning of the exam and shipped by courier to our hospital, which is 2 h away. This imposed some restrictions in the times that scans could be performed, and variability in imaging time after injection occurred in some patients because of conflicting clinic appointments or tracer delivery problems.
Scans were performed with a two-headed camera with highenergy collimation (17 mm full-width-half-maximum [FWHM] at 11 cm depth). Two to three sequential 12-min scans were performed in each patient. Scans were acquired in step-andshoot mode with 60 stops at 6°intervals with 10 s of data acquisition at each stop. Images were acquired into a 128 ϫ 128 ϫ 64 matrix. Data from the two to three acquisitions were summed during the reconstruction process. Data were prefiltered using a Hamming filter at 0.5 cycles/cm cutoff frequency. Images were reconstructed in a 128 ϫ 128 matrix using a ramp filter with a 0.947 cycle/cm cutoff frequency.
Scans were displayed on a monitor in transverse and coronal format, and weighted reprojection images (1/exponential) were also reviewed in cine mode. Scans were interpreted independently by two individuals who were board certified in radiology and nuclear medicine. Readers had access to CXR and/or CT but were blinded to histology of the lesions. Areas of increased activity over background in the region of CT or CXR abnormality were interpreted as positive. Activity in the surrounding tissue in the ipsilateral lung and in the contralateral corresponding lung region were used to determine background.
All attempts to recruit only patients who were candidates for an interventional procedure to obtain specimens for pathologic analysis were made. However, five patients refused biopsy or had insufficient follow-up at the time to characterize their lesions, and their data were excluded. One of these patients was a smoker with lung mass and brain metastases who died shortly after discovery of his lung mass. Although we assume the results in this patient were true-positive, the data from this study are not included. CT was used to characterize lesions that were attributed to normal anatomic variation or benign pathologic disease, or had disappeared on follow-up. By convention, lesions (n ϭ 2) that were stable on CT for Ն 2 years were considered benign, although there is a chance that a slow-growing malignancy could have been missed. 15 Patients with a history of previous lung primary tumor were also excluded from the study.
Of the 43 patients with adequate lesion characterization, 36 were male and 7 were female. Patients ranged in age from 39 to 81 years old (mean age, 65.3 years old). The maximal diameters of the masses ranged from 0.5 to 11 cm. There were 3 lesions of Ͻ 1 cm (7%), 21 lesions of 1 to 2 cm (49%), and 19 lesions of Ͼ 2 cm in size (44%). The mean size of lesions of Ͼ 2 cm-excluding one patient with a hilar mass and postobstructive infiltrate in whom the lesion size was difficult to measure-was 4.6 cm, and the median size was 4 cm (Fig 1) .
Results
Of the 43 patients with adequate lesion characterization, there were 26 biopsy-proven primary lung malignancies and 12 biopsy-proven benign processes (Table 1) . Five abnormalities were characterized with CT or MRI. Two abnormalities were stable for Ն 2 years, one abnormality disappeared on follow-up CT, one "lesion" was clarified as a pulmonary vein, and one "lesion" was demonstrated to be a pleural plaque. FDG SPECT results are given for all lesions in Table 2 . Representative studies are presented in Figures 2 and 3 .
Interpretive results are provided by size in Table  3 . The three lesions Ͻ 1 cm in size are not included in that table. All of these lesions were classified as true-negative interpretations. Average sensitivity, positive predictive value, and negative predictive value for lesions Ͼ 2 cm are very high (Ն 90%). For lesions between 1 and 2 cm the positive predictive value is also high (92%).
There were five congruent false-negative interpretations. All lesions were Ͻ 2 cm in size. One falsenegative interpretation occurred in a patient with diabetes who had a light lunch 2 h before FDG administration. There were two lesions that were 1.5 cm in maximal diameter and did not take up FDG. These lesions were characterized as false-negatives but the scans were interpreted as positive because of prominent uptake within mediastinal lymph nodes (Fig 4) . In addition there were two false-negative interpretations by reader 1; both lesions were Յ 2 cm in size, and low-grade activity was called positive by the second reader in these cases.
Discussion
FDG for tumor detection has been one of the most promising areas of imaging research in the past CHEST / 115 / 4 / APRIL, 1999 two decades. FDG imaging affords unique and valuable metabolic information about glucose utilization in malignant masses and has been helpful for detecting a wide variety of primary lesions. 16 -19 One of the strongest areas of FDG use is pulmonary lesion characterization using PET imaging [5] [6] [7] [8] [9] with sensitivity of 93%, specificity of 88%, and accuracy of 92% in one recent study of radiographically indeterminate nodules. 19 Establishing and maintaining a PET center is a very expensive endeavor, 20 and PET centers in our state have decreased substantially in number in the last several years. Patient access is limited and costs of clinical PET are high 20 at a time when fiscal constraints on health-care dollars are very tight. Either SPECT or hybrid coincidence-gamma camera imaging of FDG have the advantages of practicality, economy, and accessibility. These cameras can be maintained in a medium to large nuclear medicine department and used for routine nuclear medicine studies as well as high-energy imaging and can be run by the same technicians who provide routine clinical service. Currently the resolution of FDG SPECT is lower than that of PET, and the sensitivity for detection of small lesions, although controversial, is thought to be comparatively low. [11] [12] [13] [14] 21 In this study, overall sensitivity, specificity, positive predictive value, and negative predictive value for FDG SPECT were 77%, 91%, 93%, and 72%, respectively. Although these values are less than ideal, they are better than the overall sensitivity of CT or MRI, 3, 4, 22 which are currently used to characterize and stage lesions. Low values are primarily related to the low sensitivity of FDG SPECT for characterization of lesions Ͻ 2 cm in size.
Small pulmonary lesions represent a diagnostic challenge for all noninvasive imaging modalities. In this study, sensitivity in patients with lesions 1 to 2 cm in size (50%) was disappointing (Table 3) but was not unexpected. We found that small malignant lesions have an apparently low uptake on FDG SPECT that approximates background activity, and very close correlation with cross-sectional imaging was required to evaluate these masses. Comparing interpretive results demonstrates that reader 1 read with higher specificity and reader 2 with higher sensitivity. Our interobserver agreement was high at 88% (p Ͻ 0.0001). It is possible that FDG SPECT results in small lesion characterization could be improved using fusion imaging, which combines metabolic and anatomic information.
Positive predictive values for 1-to 2-cm lesions with SPECT are high (92%), suggesting that FDG SPECT might be helpful in patients with 1-to 2-cm lesions in whom a positive test might alter management (eg, confirm malignancy in patients who are not surgical candidates before radiation therapy or hasten surgical treatment vs conservative follow-up).
Additionally, there were two patient studies demonstrating negative uptake in 1.5-cm lesions with avid accumulation in mediastinal lymphadenopathy.
Interpretations were classified as false-negatives because of the lack of uptake in the primary lesions; however, the scans were interpreted as positive because of the prominent uptake in the mediastinum. From a patient-management standpoint, the sensitivity of FDG SPECT for lesions 1 to 2 cm in size would be higher at 64%.
Our results for lesions Ͼ 2 cm (n ϭ 19) in size are very high-sensitivity 100%, specificity 90%, positive predictive value 97%, and negative predictive value 100%-despite the fact that studies were performed with a 10-year-old camera and relatively low resolution of 17 mm FWHM at 11 cm depth. Our results (Table 1 ) are equivalent to PET data for lesions of this size, 19 
Conclusions
In summary, despite using 10-year-old technology, FDG SPECT appears to be equivalent to PET for characterizing pulmonary lesions Ͼ 2 cm in maximum diameter and is more accessible and costeffective than FDG PET for the large number of patients with lesions of this size. Although currently less-than-ideal clinically for characterizing lesions Ͻ 2 cm in size, FDG SPECT appears to be better than CT or MRI for characterizing pulmonary lesions, with a high positive predictive value of 92%. It is possible that with more equipment refinement, our sensitivity for small lesions will approach that of PET, as has been found by Burt et al. 23 A major effort in nuclear medicine at present is the development and validation of hybrid coincidence-gamma cameras, not FDG SPECT. At face value, the coincidence approach has much to offer. It has spatial resolution theoretically equal to PET at 5 to 6 mm FWHM. However, this approach is limited by dead-time issues that ultimately cap the achievable count rate and by a critical need for attenuation correction, which is not needed by SPECT. Our data would indicate a strong potential for FDG SPECT and the need for further improvements. We expect that even without improvements in 511-keV SPECT imaging technique, fusion imaging technique might improve the sensitivity of FDG-SPECT for characterization of small lesions. 24 In addition, we hope that future developments with the use of thicker crystals to improve sensitivity, better collimators, scatter correction, and depth-dependent resolution recovery will lead to improved spatial resolution of 5 to 9 mm and improved sensitivity so that the unique information provided by FDG imaging will be available to most patients at a reasonable cost. 
